“…There is growing evidence that sex may influence HD phenotype and neuropathology in HD rodent models and patients (Dorner et al, 2007;Bode et al, 2008;Zielonka et al, 2013). We recently showed that activation of mGluR2/3 in male and female HD mice led to differential regulation of cell signaling pathways and there are sex-specific differences in cell signaling mechanisms contributing to the pathogenesis of HD (Li et al, 2021). More importantly, we have also reported sex-specific signaling of mGluR5 in AD mice (Abd-Elrahman et al, 2020a;Abd-Elrahman and Ferguson, 2022).…”
Section: Introductionmentioning
confidence: 52%
“…We have previously reported a similar reduction in apoptotic neuronal loss and mHtt aggregates in male zQ175 mice that was attributed to reactivation of a ZBTB16-dependent autophagy pathway that facilitates the clearance of mHtt aggregates from the striatum (Abd-Elrahman et al, 2017). However, ZBTB16 autophagic pathway is regulated in a sex-specific manner in zQ175 and AD mice and therefore it is likely that the mechanisms underling such reduction in mHtt load and neuronal loss after mGluR5 antagonism are different between both sexes (Abd-Elrahman et al, 2020a;Li et al, 2021). Further investigation in the mechanism(s) underlying such reduction in mHtt pathology in CTEP-treated female zQ175 mice is required in the future.…”
Section: Discussionmentioning
confidence: 73%
“…We have previously shown that male heterozygous zQ175 mice at 12 months of age have significant deficits in both motor and cognitive functions that can be reversed by 12-week treatment with CTEP (Abd-Elrahman et al, 2017;Li et al, 2021). Here, we find that both male and female heterozygous zQ175 mice present with significant and comparable impairments in their grip strength and motor coordination that are consistent with previous findings by our group and others using the same mouse model (Menalled et al, 2012;Smith et al, 2014;Abd-Elrahman et al, 2017;Li et al, 2021). We also show that the short (4 weeks) and the long (12 weeks) treatment paradigms are to a great extent equally effective in reversing impairments in grip force and motor coordination of male zQ175 mice during rotarod test.…”
Section: Discussionmentioning
confidence: 99%
“…Slide were scanned using a Leica Aperio Slide scanner at 20× and the number of EM positive aggregates, NeuN or Iba1 positive cells were counted in representative 300 × 300 µm 2 areas of the striatum. Experimenters were blinded to analysis and six sections per mouse were analyzed and for each section two ROIs in the striatum were quantified using the cell counter tool in ImageJ (Abd-Elrahman et al, 2017, 2020b, 2021aLi et al, 2021).…”
Huntington’s disease (HD) is an inherited autosomal dominant neurodegenerative disorder that leads to progressive motor and cognitive impairment. There are currently no available disease modifying treatments for HD patients. We have previously shown that pharmacological blockade of metabotropic glutamate receptor 5 (mGluR5) signaling rescues motor deficits, improves cognitive impairments and mitigates HD neuropathology in male zQ175 HD mice. Mounting evidence indicates that sex may influence HD progression and we have recently reported a sex-specific pathological mGluR5 signaling in Alzheimer’s disease (AD) mice. Here, we compared the outcomes of treatment with the mGluR5 negative allosteric modulator CTEP (2-chloro-4-[2-[2,5-dimethyl-1-[4-(trifluoromethoxy)phenyl]imidazol-4-yl]ethynyl]pyridine) in both male and female symptomatic zQ175 mice. We found that female zQ175 mice required a longer treatment duration with CTEP than male mice to show improvement in their rotarod performance. Unlike males, chronic CTEP treatment did not improve the grip strength nor reverse the cognitive decline of female zQ175 mice. However, CTEP reduced the number of huntingtin aggregates, improved neuronal survival and decreased microglia activation in the striatum of both male and female zQ175 mice. Together, our results indicate that mGluR5 antagonism can reduce HD neuropathology in both male and female zQ175 HD mice, but sex has a clear impact on the efficacy of the treatment and must be taken into consideration for future HD drug development.
“…There is growing evidence that sex may influence HD phenotype and neuropathology in HD rodent models and patients (Dorner et al, 2007;Bode et al, 2008;Zielonka et al, 2013). We recently showed that activation of mGluR2/3 in male and female HD mice led to differential regulation of cell signaling pathways and there are sex-specific differences in cell signaling mechanisms contributing to the pathogenesis of HD (Li et al, 2021). More importantly, we have also reported sex-specific signaling of mGluR5 in AD mice (Abd-Elrahman et al, 2020a;Abd-Elrahman and Ferguson, 2022).…”
Section: Introductionmentioning
confidence: 52%
“…We have previously reported a similar reduction in apoptotic neuronal loss and mHtt aggregates in male zQ175 mice that was attributed to reactivation of a ZBTB16-dependent autophagy pathway that facilitates the clearance of mHtt aggregates from the striatum (Abd-Elrahman et al, 2017). However, ZBTB16 autophagic pathway is regulated in a sex-specific manner in zQ175 and AD mice and therefore it is likely that the mechanisms underling such reduction in mHtt load and neuronal loss after mGluR5 antagonism are different between both sexes (Abd-Elrahman et al, 2020a;Li et al, 2021). Further investigation in the mechanism(s) underlying such reduction in mHtt pathology in CTEP-treated female zQ175 mice is required in the future.…”
Section: Discussionmentioning
confidence: 73%
“…We have previously shown that male heterozygous zQ175 mice at 12 months of age have significant deficits in both motor and cognitive functions that can be reversed by 12-week treatment with CTEP (Abd-Elrahman et al, 2017;Li et al, 2021). Here, we find that both male and female heterozygous zQ175 mice present with significant and comparable impairments in their grip strength and motor coordination that are consistent with previous findings by our group and others using the same mouse model (Menalled et al, 2012;Smith et al, 2014;Abd-Elrahman et al, 2017;Li et al, 2021). We also show that the short (4 weeks) and the long (12 weeks) treatment paradigms are to a great extent equally effective in reversing impairments in grip force and motor coordination of male zQ175 mice during rotarod test.…”
Section: Discussionmentioning
confidence: 99%
“…Slide were scanned using a Leica Aperio Slide scanner at 20× and the number of EM positive aggregates, NeuN or Iba1 positive cells were counted in representative 300 × 300 µm 2 areas of the striatum. Experimenters were blinded to analysis and six sections per mouse were analyzed and for each section two ROIs in the striatum were quantified using the cell counter tool in ImageJ (Abd-Elrahman et al, 2017, 2020b, 2021aLi et al, 2021).…”
Huntington’s disease (HD) is an inherited autosomal dominant neurodegenerative disorder that leads to progressive motor and cognitive impairment. There are currently no available disease modifying treatments for HD patients. We have previously shown that pharmacological blockade of metabotropic glutamate receptor 5 (mGluR5) signaling rescues motor deficits, improves cognitive impairments and mitigates HD neuropathology in male zQ175 HD mice. Mounting evidence indicates that sex may influence HD progression and we have recently reported a sex-specific pathological mGluR5 signaling in Alzheimer’s disease (AD) mice. Here, we compared the outcomes of treatment with the mGluR5 negative allosteric modulator CTEP (2-chloro-4-[2-[2,5-dimethyl-1-[4-(trifluoromethoxy)phenyl]imidazol-4-yl]ethynyl]pyridine) in both male and female symptomatic zQ175 mice. We found that female zQ175 mice required a longer treatment duration with CTEP than male mice to show improvement in their rotarod performance. Unlike males, chronic CTEP treatment did not improve the grip strength nor reverse the cognitive decline of female zQ175 mice. However, CTEP reduced the number of huntingtin aggregates, improved neuronal survival and decreased microglia activation in the striatum of both male and female zQ175 mice. Together, our results indicate that mGluR5 antagonism can reduce HD neuropathology in both male and female zQ175 HD mice, but sex has a clear impact on the efficacy of the treatment and must be taken into consideration for future HD drug development.
“… 313 In the mouse model, activating mGluR2 and mGluR3 could enhance limb coordination by attenuating the generation of huntingtin aggregate. 316 mGluR2 and mGluR3 demonstrate protective effects on the nigrostriatal system, which restores functional deficits in Parkinson’s disease rat model. 317 , 318 Overexpression of mGluR2 in the neocortical layers, cerebellum, striatum, hippocampus, and thalamus/hypothalamus could build up glutamate-mediated excitotoxicity and promote Huntington’s disease progression.…”
Section: Gpcrs In Neuropsychiatric Diseasesmentioning
Neuropsychiatric disorders are multifactorial disorders with diverse aetiological factors. Identifying treatment targets is challenging because the diseases are resulting from heterogeneous biological, genetic, and environmental factors. Nevertheless, the increasing understanding of G protein-coupled receptor (GPCR) opens a new possibility in drug discovery. Harnessing our knowledge of molecular mechanisms and structural information of GPCRs will be advantageous for developing effective drugs. This review provides an overview of the role of GPCRs in various neurodegenerative and psychiatric diseases. Besides, we highlight the emerging opportunities of novel GPCR targets and address recent progress in GPCR drug development.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.